消息面上，太龙药业发布公告称，公司的控股股东将由泰容产投变更为江药控股，实际控制人将由郑州 高新技术产业开发区管理委员会变更为江西省国有资产监督管理委员会。 北京商报讯（记者 丁宁）12月9日，太龙药业（600222）开盘涨停，报涨停价9.44元/股，涨幅为 10.02%。 ...

经济观察报记者 张晓晖 2025年12月3日，贵州百灵（002424）（002424.SZ，下称"贵州百灵"）实际控制人、董事长姜伟发出了 一封公开信。他在信中写道： "最近几年，贵州百灵和我个人非议不断。2024年上半年，公司股票被ST处理；2025年公司完成摘帽， 各方面发展重回正轨，我作为公司控股股东却又遭到华创证券无理巨额起诉；今天，我个人又受到中国 证监会的立案调查。这一切都让我有一个强烈的感觉：似乎矛头开始转向了我个人。" 经济观察报从姜伟的代理律师（就职于通商律师事务所）处了解到，姜伟在公开信中提及的华创证券巨 额诉讼案，诉争金额达到20亿元，原本通知是12月3日在贵阳市中级人民法院开庭，由于姜伟提出反 诉，此案延期。 姜伟出生于1961年，山东栖霞人，1982年毕业于贵阳中医学院药学系（现贵州中医药大学），1996收购 了贵州安顺制药厂，也就是贵州百灵的前身。从濒临倒闭的安顺制药厂改革起步，姜伟带领企业员工历 经30余年，将企业逐步发展为产值规模年逾40亿元、税收贡献总金额70多亿元、员工人数近7000人以及 市值一度高达500亿元的苗药龙头上市公司贵州百灵。 姜伟家族曾在2015年至2017 ...

（文章来源：证券日报） 证券日报网讯 12月8日晚间，太龙药业发布公告称，最近五年公司不存在被证券监管部门和证券交易所 处罚或采取监管措施的情形。 ...

Core Viewpoint - The potential new controlling shareholder of Tai Long Pharmaceutical has emerged, with Jiang Pharmaceutical Group acquiring an 8.73% stake through a share transfer agreement, marking a significant shift in company control [2][5][6]. Group 1: Share Transfer and Control Change - Tai Long Pharmaceutical announced that its controlling shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., and other major shareholders have reached an agreement with Jiang Pharmaceutical Group for a share transfer [2]. - Jiang Pharmaceutical Group will acquire 50.1 million shares at a price of 11.043 yuan per share, totaling approximately 553 million yuan [6]. - Following the transaction, Jiang Pharmaceutical Group will hold 124.7 million shares, representing 19.23% of the total share capital, thus becoming the new controlling shareholder [5][8]. Group 2: Financial Details and Future Plans - The share transfer involves a combination of "agreement transfer + concerted action arrangement + private placement," with Jiang Pharmaceutical Group also planning to invest up to 454 million yuan in a private placement to further solidify its control [6][7]. - The private placement will involve issuing up to 74.6 million shares at a price of 6.09 yuan per share, aimed at enhancing the company's liquidity and reducing debt [7]. Group 3: Strategic Implications - Jiang Pharmaceutical Group aims to leverage its resources and brand advantages to enhance Tai Long Pharmaceutical's operational capabilities and market position [9][10]. - Tai Long Pharmaceutical specializes in drug manufacturing and R&D services, with a product portfolio that includes various traditional Chinese medicine formulations [10]. - The partnership is expected to facilitate the integration of resources and promote high-quality development within the pharmaceutical industry [10].

太龙药业（600222）(600222.SH)发布公告，2025年12月8日，公司接到控股股东泰容产投通知，其筹划 的可能导致公司控制权变更的事项已与相关方达成一致并签署协议。经公司向上海证券交易所申请，公 司股票将于2025年12月9日(星期二)开市起复牌。 ...

太龙药业12月8日公告，公司控股股东郑州泰容产业投资有限公司正在筹划的可能导致公司控制权变更 的事项已与相关方达成一致并签署协议。公司股票将于2025年12月9日开市起复牌。上述控制权变更事 项尚需履行必要的内部决策，并获得有权监管机构批准、核准、注册或同意后方可正式实施。 ...

Core Viewpoint - Tong Ren Tang (600085.SH) has received approval from Health Canada for its product Shen Ling Bai Zhu San, marking a significant step in its international expansion efforts [1][2] Group 1: Product Approval - The product Shen Ling Bai Zhu San has been granted a Class III product license by Health Canada, indicating its compliance with Canadian regulations [1] - The product is based on traditional Chinese medicine principles and is indicated for alleviating symptoms related to spleen and stomach weakness, such as reduced appetite and loose stools, as well as for relieving shortness of breath, cough, and fatigue [1] Group 2: Research and Development Investment - As of the date of the announcement, the cumulative investment in the research and development of the product amounts to approximately 2.29 million yuan, which is unaudited [2]

Core Viewpoint - Tong Ren Tang (600085) has received approval from the Canadian Ministry of Health for its product, Shen Ling Bai Zhu San, which is now registered in Canada for use in traditional Chinese medicine [1] Group 1: Company Developments - Tong Ren Tang's subsidiary, Tong Ren Tang Pharmaceutical Factory, has been granted a Class III Product License by the Canadian Ministry of Health [1] - The product Shen Ling Bai Zhu San is indicated for alleviating symptoms related to spleen and stomach weakness, including reduced appetite and loose stools, as well as for relieving shortness of breath, cough, and fatigue [1] Group 2: Product Information - Shen Ling Bai Zhu San is based on traditional Chinese medicine principles and is used to tonify the spleen and stomach while benefiting lung qi [1]

Market Overview - The traditional Chinese medicine sector experienced a decline of 0.28% on December 8, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Xinguang Pharmaceutical (300519) with a closing price of 17.34, up 3.96% and a trading volume of 131,800 shares, totaling 229 million yuan [1] - Kanghui Co., Ltd. (603139) closed at 22.35, up 2.48% with a trading volume of 20,300 shares, totaling 45.04 million yuan [1] - Conversely, Weikang Pharmaceutical (300878) saw a significant decline of 8.00%, closing at 22.66 with a trading volume of 110,800 shares, totaling 251 million yuan [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 723 million yuan from institutional investors, while retail investors saw a net inflow of 469 million yuan [2] - The capital flow for specific stocks showed: - Yunnan Baiyao (000538) had a net inflow of 26.56 million yuan from institutional investors, while retail investors had a net outflow of 6,450 yuan [3] - Kang Enbei (600572) reported a net inflow of 21.85 million yuan from institutional investors, with a net outflow of 1.92 million yuan from retail investors [3]

Core Viewpoint - Tong Ren Tang announced that its subsidiary, Tong Ren Tang Pharmaceutical Factory, received a product license (Class III) from Health Canada for its product Shen Ling Bai Zhu San, which is used to alleviate symptoms of spleen and stomach weakness [1] Group 1 - The product is a powder formulation aimed at addressing specific health issues [1] - The total investment in the product's research and development has reached approximately 2.29 million yuan [1] - The product must still undergo Canadian production quality system certification and other approvals before it can be sold in Canada, indicating uncertainty in the commercialization process [1] Group 2 - The approval of the product is not expected to have a significant impact on the company's recent operating performance [1]